METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Clinical trials for METASTATIC HORMONE SENSITIVE PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC HORMONE SENSITIVE PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC HORMONE SENSITIVE PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo tested to fight spreading prostate cancer
Disease control OngoingThis study tested whether adding a drug called enzalutamide to standard hormone therapy works better than hormone therapy alone for Chinese men with prostate cancer that has spread. It involved 180 participants and compared the two approaches to see which one better delayed cance…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Astellas Pharma China, Inc. • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
New drug combo tested to slow advanced prostate cancer progression
Disease control OngoingThis study is testing whether adding a drug called darolutamide to standard hormone therapy works better than hormone therapy alone for men whose prostate cancer has spread. Researchers want to see if this combination helps patients live longer without their cancer getting worse.…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Apr 01, 2026 21:41 UTC
-
Doctors track how real patients fare on standard prostate cancer drugs
Disease control OngoingThis study aims to understand how well two standard hormone therapy drugs work for men with advanced prostate cancer that has spread, when used in everyday medical practice. It will follow about 500 patients already scheduled to receive these treatments to see how their cancer re…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Janssen-Cilag Ltd. • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
Major trial tests if immunotherapy drug can boost prostate cancer treatment
Disease control OngoingThis large, late-stage study tested whether adding the immunotherapy drug pembrolizumab to standard hormone therapy (enzalutamide plus ADT) works better for men whose prostate cancer has spread. It aimed to see if the combination helps patients live longer and delays the cancer's…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Researchers track how doctors treat advanced prostate cancer across canada
Knowledge-focused OngoingThis study looks back at the medical records of 700 Canadian men with advanced prostate cancer that has spread to other parts of the body. Researchers want to understand what treatment combinations doctors actually use in real-world practice and how long patients stay on these tr…
Matched conditions: METASTATIC HORMONE SENSITIVE PROSTATE CANCER
Sponsor: Bayer • Aim: Knowledge-focused
Last updated Mar 23, 2026 15:17 UTC